S1PR1抗体;S1PR1 Antibody—艾普蒂

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Mouse brain tissue, Primary antibody: P11400(S1PR1 Antibody) at dilution 1/750, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

S1PR1 (sphingosine-1-phosphate receptor 1) is a G protein-coupled receptor that binds sphingosine-1-phosphate (S1P), a bioactive lipid regulating immune cell trafficking, vascular integrity, and inflammatory responses. It is highly expressed in endothelial cells and lymphocytes, where it mediates S1P signaling to control lymphocyte egress from lymphoid organs into circulation. Dysregulation of S1PR1 is implicated in autoimmune diseases, cancer, and vascular disorders, making it a therapeutic target.

S1PR1 antibodies are tools or therapeutics designed to modulate receptor activity. Function-blocking antibodies can inhibit S1P-induced signaling by preventing ligand binding or receptor internalization, thereby trapping lymphocytes in lymphoid tissues—a mechanism exploited in autoimmune disease management. For example, monoclonal antibodies targeting S1PR1 have been explored as alternatives to small-molecule S1PR1 modulators (e.g., fingolimod) to reduce systemic side effects. Conversely, agonist-like antibodies may mimic S1P to promote endothelial barrier function, potentially treating vascular leakage syndromes.

Research-grade S1PR1 antibodies are also critical for studying receptor localization, expression dynamics, and signaling pathways in disease models. Recent advances include humanized antibodies for clinical applications and bispecific designs to enhance targeting precision. Challenges remain in optimizing specificity and minimizing off-target effects, but S1PR1 antibodies hold promise for immune modulation and vascular therapeutics.